secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104969
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%
-----------------------------------------------------------------------

- Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.
- Cash $125.0M as of June 30, 2025, down from $176.3M at year-end 2024; runway into Q4 2026.
- Discontinued ADI-270 for ccRCC; workforce reduced ~30% to extend cash runway.
- Prioritizing ADI-212 (PSMA, prostate cancer); IND filing expected Q1 2026, data 2H 2026.
- Phase 1 ADI-001 autoimmune trial expanded to IIM, SPS, AAV; preliminary data expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/0000950170-25-104969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/acet-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer